Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:603229'
s PB Ratio Range Over the Past 10 Years
Min: 2.36 Med: 4.47 Max: 17.79
Current: 2.87
During the past 13 years, Zhejiang Ausun Pharmaceutical Co's highest PB Ratio was 17.79. The lowest was 2.36. And the median was 4.47.
SHSE:603229's PB Ratio is ranked better than 50.94% of 1223
companies
in the Biotechnology industry
Industry Median: 2.94
vs SHSE:603229: 2.87
During the past 12 months, Zhejiang Ausun Pharmaceutical Co's average Book Value Per Share Growth Rate was -0.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 13.80% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 16.00% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 22.40% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Zhejiang Ausun Pharmaceutical Co was 111.30% per year. The lowest was 13.80% per year. And the median was 25.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Zhejiang Ausun Pharmaceutical Co PB Ratio Related Terms
Zhejiang Ausun Pharmaceutical Co PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603229 vs VRTX, REGN, RVMD: PB Ratio Comparison
For the Biotechnology subindustry, Zhejiang Ausun Pharmaceutical Co's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhejiang Ausun Pharmaceutical Co PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhejiang Ausun Pharmaceutical Co's PB Ratio distribution charts can be found below:
* The bar in red indicates where Zhejiang Ausun Pharmaceutical Co's PB Ratio falls into.
Zhejiang Ausun Pharmaceutical Co PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Zhejiang Ausun Pharmaceutical Co (SHSE:603229) has a PB Ratio of 2.87 as of Aug. 10, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. This is 36% below median its historical median of 4.47. Over the past decade, Zhejiang Ausun Pharmaceutical Co's PB Ratio has ranged from 2.36 to 17.79. According to the industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #600 out of 1223 companies in the Biotechnology industry, placing it in the top 49.1%.
Is Zhejiang Ausun Pharmaceutical Co's PB Ratio too high?
Zhejiang Ausun Pharmaceutical Co's current PB Ratio of 2.87 is 36% below median its 10-year median of 4.47. Over the past 10 years, this metric has ranged from a low of 2.36 to a high of 17.79. The Biotechnology industry median PB Ratio is 2.94. Zhejiang Ausun Pharmaceutical Co's value of 2.87 is 2.4% below this industry median. Based on the distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #600 out of 1223 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Zhejiang Ausun Pharmaceutical Co has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zhejiang Ausun Pharmaceutical Co's PB Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zhejiang Ausun Pharmaceutical Co ranks #600 out of 1223 companies for PB Ratio. This puts Zhejiang Ausun Pharmaceutical Co in the upper half of its industry. The industry median PB Ratio is 2.94. Zhejiang Ausun Pharmaceutical Co's value of 2.87 is 2.4% below this benchmark. Historically, Zhejiang Ausun Pharmaceutical Co's own PB Ratio has ranged from 2.36 to 17.79 over the past decade. While the company's 10-year median is 4.47 vs. the industry median of 2.94, Zhejiang Ausun Pharmaceutical Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.94, based on 1,223 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zhejiang Ausun Pharmaceutical Co's current PB Ratio of 2.87 is 2.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Zhejiang Ausun Pharmaceutical Co and its competitors. For the Biotechnology industry, the median PB Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zhejiang Ausun Pharmaceutical Co's current PB Ratio is 2.87, which is 36% below median its own 10-year median of 4.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zhejiang Ausun Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co (SHSE:603229) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥9.58, compared to a current price of ¥8.17 — trading 14.7% below its estimated fair value. The current PB Ratio is 2.87, which is 36% below median its 10-year median of 4.47 and 2.4% below the Biotechnology industry median of 2.94. Zhejiang Ausun Pharmaceutical Co's overall GF Score™ is 88/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Zhejiang Ausun Pharmaceutical Co (SHSE:603229), the current PB Ratio is 2.87 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zhejiang Ausun Pharmaceutical Co (SHSE:603229) Overvalued in 2026?
Based on GuruFocus' analysis, Zhejiang Ausun Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥8.17 is trading 14.7% below its estimated GF Value™ of ¥9.58.
GuruFocus considers Zhejiang Ausun Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for SHSE:603229:
PB Ratio: 2.87 (36% below median its 10-year median of 4.47)
GF Value™: ¥9.58 vs. price of ¥8.17 (14.7% below fair value)
Industry Position: 2.4% below the Biotechnology median (#600 of 1223)
No single metric tells the full story. See the SHSE:603229 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zhejiang Ausun Pharmaceutical Co Ltd is mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates, as well as providing customized production and research for customers. Its products portfolio includes Prostaglandins and their intermediates, Raw material medicine, Fluorine series and Develop products.
88GF Score
Get the complete analysis for SHSE:603229
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603229 has been successfully added to your 
